Low Dose Naltrexone – LDN

Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn’s disease, multiple sclerosis, and complex regional pain syndrome.

Evidence shows that LDN may operate as a novel anti-inflammatory agent in the central nervous system via action on microglial cells. These effects may be unique to low dosages of naltrexone and appear to be entirely independent of naltrexone’s better-known activity on opioid receptors.

As a daily oral therapy, LDN is inexpensive and well-tolerated. Despite the initial promise of efficacy, the use of LDN for chronic disorders is still highly experimental.

LDN may represent one of the first glial cell modulators to manage chronic pain disorders.